2012-02-08
Rabies Vaccines with Isconova’s Matrix-M™ adjuvant launched in Russia
Isconova AB announces that its partner, VetBioChem, has launched two new dog and cat rabies vaccines on the Russian market. Both vaccines contain Isconova’s Matrix-MTMVet adjuvant, and Isconova will receive production revenues and royalties on sales
Since 2010 Isconova and VetBioChem, a leading Russian animal health company, have collaborated on the development of rabies vaccines for dogs and cats, and these vaccines, Rabix and Rabifel, are the first marketed veterinary vaccines using Isconova’s adjuvant Matrix-M™Vet. The agreement with VetBioChem includes revenues for Isconova for the supply of Matrix-M™Vet as well as royalties based on future sales of the rabies vaccines.
Russell Greig, acting CEO of Isconova, commented;
“We are very pleased that Rabix and Rabifel have been launched in Russia where rabies is a serious problem for both animals and humans. The launch of these Matrix-M™ based vaccines is further validation of our adjuvant technology platform and marks another step towards launching additional vaccines based on Isconova’s enabling technology in new markets.”
For more information, please contact:
Gerd Rundström, COO, Isconova AB
Tel +46 18 16 17 06